Sean Ronnekleiv-Kelly

Assistant Professor

University of Wisconsin School of Medicine and Public Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Sean Ronnekleiv-Kelly is an Assistant Professor at the University of Wisconsin-Madison School of Medicine and Public Health in the United States. His research areas focus on the interactions between the circadian clock and pancreatic cancer, as well as the role of Pdx1 expression in hematopoietic cells in relation to leukemia. Additionally, he examines the effects of chronic jetlag on pancreatic neoplasia in conditional Kras-mutant mice.

Articles (8)

Year:

2026

The circadian clock is tightly connected to metabolism, which is evident in various metabolic processes performed by the liver. Perturbation of these processes due to circadian dysregulation leads to liver specific pathology. The liver is composed of multiple different cell populations each with distinct functions contributing to organ homeostasis, but individual cell population contributions to circadian clock function is not yet known. Single-cell RNA sequencing provides the opportunity to understand clock function and oscillating gene expression within an organ system at the individual cell population level that would allow for better understanding of the crosstalk between the circadian clock and metabolic pathways within the liver. In the past, barriers to achieving this goal included complexity associated with generating single-cell RNA sequencing time series data as well as the complexity of data analysis. Here, we established a protocol that enabled the generation of murine liver cell population time series data, as well as a methodological approach to evaluate the core molecular clock and oscillating gene expression in individual cell populations. Using a combination of normalized coefficient of variation, clock-correlation and aggregate pseudobulk, we found a robust and aligned circadian clock in each of the cell populations. We then employed a pseudoreplicate / pseudobulk strategy to identify oscillating gene expression and benchmarked against bulk RNA sequencing data; we demonstrated that many metabolic genes were oscillating in several of the cell populations, including non-hepatocyte clusters. Finally, we identified oscillating genes unique to specific cell populations that play critical roles in liver function. The findings in this study lay an important foundation for understanding clock function and contributions of oscillating gene function at the individual cell population level in liver.

Year:

2025

Purpose Incidental detection of pancreas lesions (IPLs) is common and creates an opportunity to intercept pancreatic ductal adenocarcinoma (PDAC). However, identifying patients at risk for progression who can benefit from surgical resection remains challenging. The current role of blood tests for risk stratification in patients with IPLs is limited. Methods We evaluated the performance of circulating glycoproteins (CA19-9, CEA and CA125), plasma DNA fragmentation analysis, and their combination, in 99 asymptomatic patients with IPLs, for detection of advanced pathology (high-grade dysplasia or invasive carcinoma). Plasma DNA fragmentation was analyzed using a machine learning model, adapted to detect PDAC in 242 patients with cancer and 300 healthy individuals. Results During 18.8 months of median follow-up by a multidisciplinary clinical team, 11 of 99 patients with IPLs were diagnosed with advanced pathology. We observed area under the receiver operating characteristic curves (AUROCs) of 0.78, 0.63, 0.54 and 0.74 using CA19-9, CEA, CA125 and plasma DNA fragmentation, respectively. Combined analysis of CA19-9, CA125 and plasma DNA fragmentation showed an AUROC of 0.93, with 91% sensitivity and 53% positive predictive value (PPV) at 90% specificity. In a subset of 25 patients with histologically confirmed diagnoses, AUROC improved to 0.96 and PPV improved to 91%. In one patient with an equivocal initial endoscopy, multi-analyte blood analysis predicted cancer 3 months before diagnosis of stage IA cancer. Conclusion Our results demonstrate a multianalyte blood test combining glycoprotein biomarkers with plasma DNA fragmentation could complement current clinical workflows for cancer detection in patients with IPLs.

Year:

2024

Fibrolamellar carcinoma (FLC) is a rare malignancy disproportionately affecting adolescents and young adults with no standard of care. FLC is characterized by thick stroma, which has long suggested an important role of the tumor microenvironment. Over the past decade, several studies have revealed aberrant markers and pathways in FLC. However, a significant drawback of these efforts is that they were conducted on bulk tumor samples. Consequently, identities and roles of distinct cell types within the tumor milieu, and the patterns of intercellular communication, have yet to be explored. In this study we unveil cell-type specific gene signatures, transcription factor networks, and super-enhancers in FLC using a multi-omics strategy that leverages both single-nucleus ATAC-seq and single-nucleus RNA-seq. We also infer completely rewired cell-to-cell communication patterns in FLC including signaling mediated by SPP1-CD44, MIF-ACKR3, GDF15-TGFBR2, and FGF7-FGFR. Finally, we validate findings with loss-of-function studies in several models including patient tissue slices, identifying vulnerabilities that merit further investigation as candidate therapeutic targets in FLC.

Year:

2024

Fibrolamellar carcinoma (FLC) is a rare liver cancer that disproportionately affects adolescents and young adults. Currently, no standard of care is available and there remains a dire need for new therapeutics. Most patients harbor the fusion oncogene DNAJB1-PRKACA (DP fusion), but clinical inhibitors are not yet developed and it is critical to identify downstream mediators of FLC pathogenesis. Here, we identify long noncoding RNA LINC00473 among the most highly upregulated genes in FLC tumors and determine that it is strongly suppressed by RNAi-mediated inhibition of the DP fusion in FLC tumor epithelial cells. We show by loss- and gain-of-function studies that LINC00473 suppresses apoptosis, increases the expression of FLC marker genes, and promotes FLC growth in cell-based and in vivo disease models. Mechanistically, LINC00473 plays an important role in promoting glycolysis and altering mitochondrial activity. Specifically, LINC00473 knockdown leads to increased spare respiratory capacity, which indicates mitochondrial fitness. Overall, we propose that LINC00473 could be a viable target for this devastating disease.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Taran Gujral

Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Praveen Sethupathy

Professor

Cornell University

UNITED STATES
View details

John D. Gordan

University of California

UNITED STATES
View details

Muhammed Murtaza

Associate Professor

University of Wisconsin-Madison

UNITED STATES
View details

Syed Nabeel Zafar

Assistant Professor, surgical oncology

University of Wisconsin-Madison

UNITED STATES
View details